ORM-5029
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


ORM-5029
Target :
Antibody-Drug Conjugates (ADCs)Related Pathways :
Antibody-drug Conjugate/ADC RelatedBioactivity :
ORM-5029 is the first antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2), combining the highly potent GSPT1 degrader SMol006 with Pertuzumab. It is applicable in cancer research.Shipping Conditions :
Cool packStorage Temperature :
-20°C

